A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 0.9408 USD -2.58% Market Closed
Market Cap: 89.7m USD
Have any thoughts about
Assertio Holdings Inc?
Write Note

Assertio Holdings Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Assertio Holdings Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Interest Income Expense
$15.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Interest Income Expense
$745m
CAGR 3-Years
19%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Interest Income Expense
$859m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
-11%
Eli Lilly and Co
NYSE:LLY
Interest Income Expense
-$426.9m
CAGR 3-Years
-100%
CAGR 5-Years
-12%
CAGR 10-Years
-36%
No Stocks Found

Assertio Holdings Inc
Glance View

Market Cap
89.7m USD
Industry
Pharmaceuticals

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
1.5439 USD
Undervaluation 39%
Intrinsic Value
Price
A

See Also

What is Assertio Holdings Inc's Interest Income Expense?
Interest Income Expense
15.8m USD

Based on the financial report for Sep 30, 2024, Assertio Holdings Inc's Interest Income Expense amounts to 15.8m USD.

Back to Top